Nang Kuang Pharmaceutical Co (TPE:1752) Ending Cash Position: NT$364 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1752 Nang Kuang Pharmaceutical Co Ltd TPE:1752
92 GF Score
Price NT$31.85
GF Value NT$40.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Nang Kuang Pharmaceutical Co Ending Cash Position?

Nang Kuang Pharmaceutical Co TPE:1752 +0.47% 92 Ending Cash Position is NT$364 Mil as of Jun. 2026. GuruFocus rates TPE:1752 with a GF Score™ of 92/100 and a GF Value™ of NT$40.91 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Nang Kuang Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$364 Mil.

Nang Kuang Pharmaceutical Co's quarterly Ending Cash Position declined from Dec. 2025 (NT$346 Mil) to Mar. 2026 (NT$327 Mil) but then increased from Mar. 2026 (NT$327 Mil) to Jun. 2026 (NT$364 Mil).

Nang Kuang Pharmaceutical Co's annual Ending Cash Position declined from Dec. 2023 (NT$378 Mil) to Dec. 2024 (NT$302 Mil) but then increased from Dec. 2024 (NT$302 Mil) to Dec. 2025 (NT$346 Mil).

Nang Kuang Pharmaceutical Co Ending Cash Position Related Terms

Nang Kuang Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Nang Kuang Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nang Kuang Pharmaceutical Co Ending Cash Position Chart

Nang Kuang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 417.12 401.20 378.48 301.54 345.67

Nang Kuang Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.49 263.25 345.67 327.26 363.56
TPE:1752
92GF Score
Nang Kuang Pharmaceutical Co Ltd TPE:1752
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nang Kuang Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nang Kuang Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=301.542+44.127
=346

Nang Kuang Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=327.26+36.295
=364

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$364 Mil mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a Ending Cash Position of NT$364 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nang Kuang Pharmaceutical Co and its competitors.
Is Nang Kuang Pharmaceutical Co's Ending Cash Position too high?
Nang Kuang Pharmaceutical Co's current Ending Cash Position is NT$364 Mil. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's Ending Cash Position compare to ISRG and BDX?
Nang Kuang Pharmaceutical Co's Ending Cash Position of NT$364 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nang Kuang Pharmaceutical Co and its competitors. Nang Kuang Pharmaceutical Co's current Ending Cash Position is NT$364 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$40.91, compared to a current price of NT$31.85 — trading 22.1% below its estimated fair value. The current Ending Cash Position is NT$364 Mil. Nang Kuang Pharmaceutical Co's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current Ending Cash Position is NT$364 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?

Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$31.85 is trading 22.1% below its estimated GF Value™ of NT$40.91. GuruFocus considers Nang Kuang Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TPE:1752:

  • Ending Cash Position: NT$364 Mil
  • GF Value™: NT$40.91 vs. price of NT$31.85 (22.1% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nang Kuang Pharmaceutical Co Business Description

Address Section 8, Civic Boulevard, 5th Floor, No. 205, Nangang District, Taipei, TWN, 115
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
92GF Score

Get the complete analysis for TPE:1752

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.85
Price
NT$40.91
GF Value